PMID- 27142166
OWN - NLM
STAT- MEDLINE
DCOM- 20170109
LR  - 20181202
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 14
DP  - 2016 May 3
TI  - ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to 
      treatment efficacy.
PG  - 139
LID - 10.1186/s12957-016-0893-6 [doi]
LID - 139
AB  - BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangement is detected in 3% 
      to 13% of non-small cell lung carcinoma patients, and these patients benefit from 
      ALK inhibitors. The aim of this study was to determine the prevalence, the 
      clinical and histological characteristics and the treatment outcomes of 
      ALK-rearranged lung adenocarcinoma using immunohistochemistry (IHC) IHC, reverse 
      transcription polymerase chain reaction (RT-PCR) and fluorescence in situ 
      hybridization (FISH) methodologies. METHODS: A total of 268 pulmonary 
      adenocarcinoma patients were screened for ALK expression by ALK IHC, which was 
      confirmed by FISH and/or RT-PCR for ALK gene rearrangement. The treatment 
      outcomes of ALK-rearranged patients were retrospectively reviewed. RESULTS: ALK 
      gene rearrangement was identified in 26 cases (9.7%) with no EGFR co-mutation, 
      and it showed significant associations with younger age, female sex and 
      non-smoker status (p < 0.05). A cribriform growth pattern was identified as the 
      dominant histologic feature, and a solid signet ring cell component was focally 
      present in a minority of the cases. Among 12 ALK-rearranged patients with 
      conventional treatment, seven cases in the early stage of disease were cured and 
      alive, and five patients in the late stage of the disease progressed and died, 
      with a median overall survival (OS) at 14 months. Of the 14 patients receiving 
      crizotinib, all of them had clinical benefit from crizotinib treatment, with one 
      patient having a complete response (CR), 12 patients having a partial response 
      (PR) and one patient having stable disease (SD). On the cutoff date, six of 14 
      patients were continuing crizotinib treatment with a median time of response of 
      7.5 (3-13) months, while eight patients had disease progression, and five of them 
      died with a median OS at 8 months. CONCLUSION: ALK gene rearrangement tended to 
      occur in younger, non-smoking, female patients. ALK IHC is a reliable screening 
      method to detect ALK gene rearrangement. Crizotinib therapy provided treatment 
      benefit in ALK-rearranged adenocarcinoma patients especially in advanced stages 
      of the disease.
FAU - Incharoen, Pimpin
AU  - Incharoen P
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Reungwetwattana, Thanyanan
AU  - Reungwetwattana T
AD  - Division of Medical Oncology, Department of Medicine, Faculty of Medicine 
      Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Saowapa, Sakditad
AU  - Saowapa S
AD  - Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
FAU - Kamprerasart, Kaettipong
AU  - Kamprerasart K
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Pangpunyakulchai, Duangjai
AU  - Pangpunyakulchai D
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Arsa, Lalida
AU  - Arsa L
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Jinawath, Artit
AU  - Jinawath A
AD  - Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand. artit.jinp@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20160503
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/drug therapy/*genetics/secondary
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anaplastic Lymphoma Kinase
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Rearrangement
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Lung Neoplasms/drug therapy/*genetics/pathology
MH  - Lymphatic Metastasis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Young Adult
PMC - PMC4855782
OTO - NOTNLM
OT  - ALK gene rearrangement
OT  - Crizotinib
OT  - efficacy
OT  - pulmonary adenocarcinoma
EDAT- 2016/05/05 06:00
MHDA- 2017/01/10 06:00
PMCR- 2016/05/03
CRDT- 2016/05/05 06:00
PHST- 2016/01/05 00:00 [received]
PHST- 2016/04/21 00:00 [accepted]
PHST- 2016/05/05 06:00 [entrez]
PHST- 2016/05/05 06:00 [pubmed]
PHST- 2017/01/10 06:00 [medline]
PHST- 2016/05/03 00:00 [pmc-release]
AID - 10.1186/s12957-016-0893-6 [pii]
AID - 893 [pii]
AID - 10.1186/s12957-016-0893-6 [doi]
PST - epublish
SO  - World J Surg Oncol. 2016 May 3;14:139. doi: 10.1186/s12957-016-0893-6.